Literature DB >> 1002751

Joint replacement surgery in patients under thirty.

R S Bsila, A E Inglis, C S Ranawat.   

Abstract

Forty-five patients, twenty-six of them with juvenile rheumatoid arthritis, had sixty-seven total hip arthroplasties. The patients' ages ranged from twelve to twenty-nine years. An over-all good result was demonstrated in 93 per cent of the patients had a poor result, in 6.9 per cent. The average follow-up period was 32.5 months. Careful planning in severely dysplastic joints should be done.

Entities:  

Mesh:

Year:  1976        PMID: 1002751

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

1.  Function and fixation of total hip arthroplasty in patients 25 years of age or younger.

Authors:  John C Clohisy; Jeremy M Oryhon; Thorsten M Seyler; Christopher W Wells; Steve S Liu; John J Callaghan; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

2.  Survival of Bi-Metric femoral stems in 77 total hip arthroplasties for juvenile chronic arthritis.

Authors:  C C Lybäck; C O Lybäck; A Kyrö; H J Kautiainen; E A Belt
Journal:  Int Orthop       Date:  2004-08-14       Impact factor: 3.075

3.  Long-term results of Bernese periacetabular osteotomy using a dual approach in hip dysplasia.

Authors:  Hyun Chul Shon; Woo Sung Park; Jae-Suk Chang; Seong-Eun Byun; Dong-Wook Son; Hee Jin Park; Sang Hoon Ha; Ki Tae Park; Jai Hyung Park
Journal:  Arch Orthop Trauma Surg       Date:  2021-08-03       Impact factor: 3.067

Review 4.  Management of temporomandibular ankylosis--compromise or individualization--a literature review.

Authors:  Katarzyna Sporniak-Tutak; Joanna Janiszewska-Olszowska; Robert Kowalczyk
Journal:  Med Sci Monit       Date:  2011-05

5.  Ten-year survival rate after rotational acetabular osteotomy in adulthood hip dysplasia.

Authors:  Masamitsu Tomioka; Yutaka Inaba; Naomi Kobayashi; Taro Tezuka; Hyonmin Choe; Hiroyuki Ike; Tomoyuki Saito
Journal:  BMC Musculoskelet Disord       Date:  2017-05-15       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.